- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 12.08. | eXoZymes Provides Second Quarter 2025 Update at 5PM EST Today | 276 | ACCESS Newswire | Management to host earnings call at 5:00PM Eastern Time, today. LOS ANGELES, CALIFORNIA / ACCESS Newswire / August 12, 2025 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-engineered... ► Artikel lesen | |
| 12.08. | EXOZYMES INC. - 10-Q, Quarterly Report | 4 | SEC Filings | ||
| 08.08. | eXoZymes to Host Second Quarter 2025 Update on Tuesday August 12, 2025, at 5PM EST | 266 | ACCESS Newswire | LOS ANGELES, CA / ACCESS Newswire / August 7, 2025 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into nutraceuticals... ► Artikel lesen | |
| 29.07. | eXoZymes achieves 99% purity in lab-scale NCT production | 1 | Investing.com | ||
| 29.07. | eXoZymes Details Biomanufacturing Breakthrough: 4 Grams of NCT with Over 99% Purity | 387 | ACCESS Newswire | Using eXoZymes' AI-driven exozymes platform, NCTx has demonstrated lab scale validation with 4 grams of NCT produced at a 96% yield and with a purity higher than 99%.NCT project went from concept to... ► Artikel lesen | |
| 22.07. | eXoZymes meldet Durchbruch bei Bioproduktion von NCT | 3 | Investing.com Deutsch | ||
| 22.07. | eXoZymes achieves breakthrough in NCT biomanufacturing process | 2 | Investing.com | ||
| EXOZYMES Aktie jetzt für 0€ handeln | |||||
| 22.07. | eXoZymes Biomanufacturing Breakthrough: From Concept to Gram-Scale NCT in Only 5 Months | 420 | ACCESS Newswire | N-trans-caffeoyltyramine (NCT) is a natural bioactive compound attracting considerable interest from researchers for its potential role in healthy liver fat metabolism, gut barrier function, and mitochondrial... ► Artikel lesen | |
| 07.07. | Hedge Fund and Insider Trading News: Bill Ackman, Michael Platt, Scott Bessent, Point72 Asset Management, Berkshire Hathaway, Lakehouse Capital, Exozymes Inc (EXOZ), and More | 38 | Insider Monkey | ||
| 26.06. | eXoZymes Selected as Core Industry Partner in $9M NSF-Funded Initiative to Advance Modular Cell-Free Biomanufacturing | 331 | ACCESS Newswire | MONROVIA, CA / ACCESS Newswire / June 26, 2025 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into nutraceuticals, medicines... ► Artikel lesen | |
| 20.06. | EXOZYMES INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 16.05. | eXoZymes Highlights Scalable Biomanufacturing Platform and First Spinout, NCTx, on Grow Everything Podcast | 439 | ACCESS Newswire | MONROVIA, CALIFORNIA / ACCESS Newswire / May 16, 2025 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into nutraceuticals... ► Artikel lesen | |
| 13.05. | eXoZymes reports Q1 results | 2 | Seeking Alpha | ||
| 12.05. | eXoZymes Provides First Quarter 2025 and NCTx Subsidiary Update at 5PM EST Today | 300 | ACCESS Newswire | Management to host earnings call at 5:00PM Eastern Time, today. MONROVIA, CA / ACCESS Newswire / May 12, 2025 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-engineered enzymes that... ► Artikel lesen | |
| 12.05. | EXOZYMES INC. - 10-Q, Quarterly Report | 3 | SEC Filings | ||
| 07.05. | eXoZymes to Host First Quarter 2025 and Subsidiary NCTx Update on Monday May 12, 2025, at 5PM EST | 363 | ACCESS Newswire | MONROVIA, CA / ACCESS Newswire / May 7, 2025 / eXoZymes Inc. (NASDAQ:EXOZ) ["eXoZymes"] - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into nutraceuticals, medicines,... ► Artikel lesen | |
| 06.05. | eXoZymes Launches Subsidiary, NCTx, to Unlock a Promising Compound for Gut and Liver Health | 292 | ACCESS Newswire | N-trans-caffeoyltyramine (NCT) is a natural product compound attracting considerable interest from researchers and drug developers for its potential role in healthy liver fat metabolism, gut barrier... ► Artikel lesen | |
| 25.04. | EXOZYMES INC. - S-8, Securities to be offered to employees in employee benefit plans | 2 | SEC Filings | ||
| 21.04. | eXoZymes Inc.: Bringing clarity and precision to the cell-free space by introducing exozymes | 1 | GlobeNewswire (USA) | ||
| 12.04. | New to The Street Announces Bloomberg Television Lineup for Saturday, April 12 at 6:30 PM ET Featuring Health In Tech CFO Julia Qian, BIOVie's Dr. Joseph Palumbo, The Sustainable Green Team with Kevin Harrington and Tony Raynor, and eXoZymes Vice Presiden | 924 | ACCESS Newswire | New to The Street debuts its inaugural restaurant segment featuring BlackBarn with owner and chef John Doherty NEW YORK CITY, NY / ACCESS Newswire / April 12, 2025 / New to The Street, a leading financial... ► Artikel lesen |
1 2 Weiter >>
39 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 96,05 | +0,05 % | BioNTech erreicht Phase-3-Erfolg bei Brustkrebsstudie mit BNT323 | BioNTech hat gemeinsam mit DualityBio einen wichtigen Studienerfolg erzielt: In einer von DualityBio in China durchgeführten Phase-3-Studie erreichte der Antikörper-Wirkstoff-Kandidat Trastuzumab Pamirtecan... ► Artikel lesen | |
| QIAGEN | 40,390 | +0,44 % | JEFFERIES stuft QIAGEN NV auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Qiagen mit einem Kursziel von 57 US-Dollar auf "Buy" belassen. Dies schrieb Analyst Tycho Peterson in seinem am Freitag... ► Artikel lesen | |
| NUVALENT | 80,89 | +1,53 % | Nuvalent, Inc.: Nuvalent Highlights Pipeline and Business Achievements, Reiterates Key Anticipated Milestones, and Reports Second Quarter 2025 Financial Results | Initiated rolling NDA submission for zidesamtinib for TKI pre-treated patients with advanced ROS1-positive NSCLC, with target completion in the third quarter of... ► Artikel lesen | |
| DYNE THERAPEUTICS | 14,220 | +7,40 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces FDA Breakthrough Therapy Designation for DYNE-251 in Duchenne Muscular Dystrophy (DMD) | - Data from the DELIVER registrational expansion cohort is expected in late 2025, with a potential BLA submission for U.S. accelerated approval anticipated in early 2026 - WALTHAM, Mass., Aug.... ► Artikel lesen | |
| EVOTEC | 5,856 | +2,70 % | Rheinmetall Aktie: Das ist verdächtig! - Evotec, Delivery Hero, Indus, Smartbroker und Verbio im Marktbericht Börse Frankfurt | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 4,610 | +1,99 % | Recursion Pharmaceuticals: Recursion Reports Second Quarter 2025 Financial Results and Provides Business Update | SALT LAKE CITY, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates and... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 50,38 | +3,81 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Second Quarter 2025 Financial Results and Recent Highlights | Aligned with FDA on del-brax accelerated and full approval pathways for FSHD, reported positive topline data from Phase 1/2 FORTITUDE trial, and initiated global... ► Artikel lesen | |
| BEAM THERAPEUTICS | 20,890 | +12,68 % | Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease | CAMBRIDGE, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 25,980 | +9,16 % | Summit Therapeutics stock maintains Buy rating at H.C. Wainwright on ivonescimab progress | ||
| MINERALYS THERAPEUTICS | 34,750 | +4,92 % | Mineralys reports positive subgroup data for hypertension drug | ||
| VERA THERAPEUTICS | 24,220 | +10,59 % | Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | BRISBANE, Calif., Sept. 05, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on September 4, 2025, the Compensation Committee of Vera's Board of Directors granted... ► Artikel lesen | |
| CG ONCOLOGY | 33,105 | +7,00 % | CG Oncology Inc.: CG Oncology Completes Enrollment in PIVOT-006 | - Rapid enrollment underscores high unmet need in intermediate-risk non-muscle invasive bladder cancer (NMIBC) -- One of the largest randomized phase 3 studies in this patient population will encompass... ► Artikel lesen | |
| MOONLAKE IMMUNOTHERAPEUTICS | 59,42 | -0,50 % | MoonLake Immunotherapeutics AG: MoonLake Immunotherapeutics Reports Second Quarter 2025 Financial Results and Provides a Business Update | Phase 3 VELA program in hidradenitis suppurativa (HS) on track for an expected primary endpoint readout around September 2025 and an expected submission of a Biologic License Application (BLA) in the... ► Artikel lesen | |
| ARS PHARMACEUTICALS | 10,090 | -5,61 % | Roth/MKM initiates ARS Pharmaceuticals stock with Buy rating on neffy potential | ||
| ARCUTIS BIOTHERAPEUTICS | 17,200 | +6,11 % | Arcutis Biotherapeutics, Inc.: Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | WESTLAKE VILLAGE, Calif., Sept. 05, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations... ► Artikel lesen |
EXOZYMES INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 10,250 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu EXOZYMES INC finden Sie auf Wallstreet Online.